Thursday, February 22, 2024
wellness India Expo
Home Tags ZYIL1

Tag: ZYIL1

Zydus Lifesciences initiates Phase II clinical trial of ZYIL1, a potential...

The USFDA has granted Zydus an ‘Orphan Drug Designation’ for ZYIL1 to treat patients with Cryopyrin Associated Periodic Syndrome (CAPS), a rare auto-inflammatory disease

Zydus to present on ZYIL1 at the International Congress of Parkinson’s...

ZYIL1 decreased α synuclein expression and improved motor function in non-clinical models of Parkinson’s Disease

Zydus granted orphan drug designation by USFDA for ZYIL1 in treatment...

Orphan drug designation by USFDA for ZYIL1, provides eligibility for certain development incentives, including tax credits for qualified clinical testing, prescription drug user fee exemptions and seven-year marketing exclusivity

Zydus achieves positive Phase 2 Proof-of-Concept of NLRP3 inhibitor, ZYIL1 in...

The company is now planning to conduct further pivotal clinical trials and is committed to develop ZYIL1 for patients living with CAPS and other chronic inflammatory diseases

Zydus gets go ahead for phase-2 clinical trial of its novel...

The company will soon begin the Phase II (a) clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Cryopyrin-Associated Periodic Syndrome (CAPS), a rare life-long auto-inflammatory condition in Australia